三元基因营收微涨，63岁董事长程永庆年薪138万元、66岁哥哥任副董事长

Financial Performance - In the first half of 2025, the company's operating revenue was 118 million yuan, a year-on-year increase of 1.02% [1] - The net profit attributable to shareholders was -6.4654 million yuan, a year-on-year decline of 166.89% [1] - The non-recurring net profit attributable to shareholders was -7.2552 million yuan, a year-on-year decrease of 181.62% [1] - Basic earnings per share were -0.05 yuan [1] Profitability Metrics - The gross profit margin for the first half of 2025 was 77.20%, a decrease of 4.06 percentage points year-on-year [1] - The net profit margin was -5.46%, down 13.71 percentage points compared to the same period last year [1] Expense Analysis - Total operating expenses for the first half of the year were 95.1775 million yuan, an increase of 12.3226 million yuan year-on-year [1] - The expense ratio was 80.41%, up 9.70 percentage points from the previous year [1] - Sales expenses increased by 0.09%, management expenses rose by 18.81%, R&D expenses surged by 103.31%, and financial expenses grew by 64.37% year-on-year [1] Executive Compensation - The chairman and general manager, Cheng Yongqing, received a salary of 1.377 million yuan in 2024, a decrease of 12.57% from the previous year's salary of 1.575 million yuan [3] Company Background - Beijing Sanyuan Gene Pharmaceutical Co., Ltd. was established on September 24, 1992, and went public on January 8, 2021 [6] - The company is located in the biomedical base in Daxing District, Beijing, and is engaged in the research, development, production, and sales of biomedicine [6]